Karin Bergmann

Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis

Causes of Medication Administration Errors in Hospitals: a Systematic Review of Quantitative and Qualitative Evidence

Functional and morphological study of cultured pancreatic islets treated with cyclosporine

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

Type 2 diabetes

Global aetiology and epidemiology of type 2 diabetes mellitus and its complications

High-risk subgroups of patients with non-Q wave myocardial infarction based on direction and severity of ST segment deviation

Cardiac Myxomas

The TIMI Risk Score for Unstable Angina/Non–ST Elevation MI

Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition

Recent Advances in Insulin Therapy

Diagnostic and surgical aspects of left atrial tumors

One‐year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal‐time insulin: the EDITION 1 12‐month randomized trial, including 6‐month extension

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients

Pathophysiology of Type 2 Diabetes Mellitus

Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice

Prevalence and Nature of Medication Administration Errors in Health Care Settings: A Systematic Review of Direct Observational Evidence

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary

Prevention of toxic effects of cyclosporin on pancreatic B-cells of rats by Rioprostil, a new prostaglandin analogue.

Prospective pilot intervention study to prevent medication errors in drugs administered to children by mouth or gastric tube: a programme for nurses, physicians and parents

New Insulin Glargine 300 Units·mL−1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units·mL−1

Assessment of myocardial infarct size in clinical practice.

Low within‐ and between‐day variability in exposure to new insulin glargine 300 U/ml

Röntgenologische Differentialdiagnostik von intrakavitären Tumoren und Thromben des Herzens

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml